BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...

Goldman Sachs indicated it sees "additional upside" potential for BridgeBio stock as the company continues to execute its commercial strategy for Attruby in ATTR-CM (transthyretin amyloid ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also ...

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy ...

1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...